Hyloris And Hikma Ally On Maxigesic IV In US
Firms Strike Marketing Partnership For Intravenous Paracetamol/Ibuprofen
Hyloris has secured Hikma as its US marketing partner for Maxigesic IV. The deal gives Hyloris access to Hikma’s presence in complex, injectable hospital products while aligning with Hikma’s push into differentiated treatments.
